This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foult, J. M. Articles by Nitenberg, A. Search for Related Content PubMed PubMed Citation Articles by Foult, J. M. Articles by Nitenberg, A.

Circulation, Vol 77, 337-344, Copyright © 1988 by American Heart Association

ARTICLES

Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique

JM Foult, O Tavolaro, I Antony and A Nitenberg
CHU Xavier-Bichat, INSERM U.251, Paris, France.

Angiotensin II elicits contractile responses in the coronary arteries and myocardial tissue, which suggests that blockade of the renin- angiotensin system by specific agents should lead to both coronary vasodilation and an alteration of left ventricular inotropism. The present work was designed to delineate--independently from its systemic effects--the intrinsic actions of an angiotensin converting-enzyme inhibitor on the coronary circulation and left ventricular function. To minimize peripheral effects, a bilateral intracoronary infusion of enalaprilat (0.05 mg.min-1, 1 ml.min-1 in each coronary artery) was performed in 16 patients with dilated cardiomyopathy. All patients had normal coronary arteriograms. In 12 patients (group I) the intracoronary infusion of enalaprilat resulted in minimal peripheral changes, with a 5% reduction in the mean aortic pressure (p less than .05) and no significant alteration in indexes of preload, i.e., left ventricular end-diastolic pressure and volume, or of afterload, i.e., left ventricular end-systolic stress and systemic resistances. Myocardial oxygen consumption was also unaffected by the intracoronary infusion of enalaprilat. Coronary vasodilation was demonstrated by a significant elevation of coronary sinus blood flow (+19%, from 181 +/- 73 to 214 +/- 79 ml.min-1, p less than .001) and a reduction of coronary resistance (-18%, from 0.51 +/- 0.17 to 0.41 +/- 0.15 mm Hg.ml- 1.min, p less than .001), with a parallel increase in coronary sinus oxygen content and pressure (both p less than .05). Oxygen extraction by the myocardium was reduced (p less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. J. Zeitz, D. J. Campbell, and J. D. Horowitz Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans Hypertension, March 1, 2003; 41(3): 482 - 487. [Abstract] [Full Text] [PDF]

				L. A. Nikolaidis, A. Doverspike, R. Huerbin, T. Hentosz, and R. P. Shannon Angiotensin-Converting Enzyme Inhibitors Improve Coronary Flow Reserve in Dilated Cardiomyopathy by a Bradykinin-Mediated, Nitric Oxide-Dependent Mechanism Circulation, June 11, 2002; 105(23): 2785 - 2790. [Abstract] [Full Text] [PDF]

				I. S. Wittstein, D. A. Kass, P. H. Pak, W. L. Maughan, B. Fetics, and J. M. Hare Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., August 1, 2001; 38(2): 429 - 435. [Abstract] [Full Text] [PDF]

				K. E Loke, E. J Messina, E. G Shesely, G. Kaley, and T. H Hintze Potential role of eNOS in the therapeutic control of myocardial oxygen consumption by ACE inhibitors and amlodipine Cardiovasc Res, January 1, 2001; 49(1): 86 - 93. [Abstract] [Full Text] [PDF]

				A. Saino, G. Pomidossi, R. Perondi, A. Morganti, L. Turolo, and G. Mancia Modulation of Sympathetic Coronary Vasoconstriction by Cardiac Renin-Angiotensin System in Human Coronary Heart Disease Circulation, May 16, 2000; 101(19): 2277 - 2283. [Abstract] [Full Text] [PDF]

				D. J. Campbell, A.-M. Duncan, and A. Kladis Angiotensin-Converting Enzyme Inhibition Modifies Angiotensin but Not Kinin Peptide Levels in Human Atrial Tissue Hypertension, August 1, 1999; 34(2): 171 - 175. [Abstract] [Full Text] [PDF]

				L. S. Zisman Inhibiting Tissue Angiotensin-Converting Enzyme : A Pound of Flesh Without the Blood? Circulation, December 22, 1998; 98(25): 2788 - 2790. [Full Text] [PDF]

				M. A. Mathier, G. A. Rose, M. A. Fifer, M. I. Miyamoto, R. E. Dinsmore, H. H. Castano, G. W. Dec, I. F. Palacios, and M. J. Semigran Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., July 1, 1998; 32(1): 216 - 224. [Abstract] [Full Text] [PDF]

				M. Kyriakidis, F. Triposkiadis, J. Dernellis, A. E. Androulakis, P. Mellas, G. A. Kelepeshis, and J. E. Gialafos Effects of Cardiac Versus Circulatory Angiotensin-Converting Enzyme Inhibition on Left Ventricular Diastolic Function and Coronary Blood Flow in Hypertrophic Obstructive Cardiomyopathy Circulation, April 14, 1998; 97(14): 1342 - 1347. [Abstract] [Full Text] [PDF]

				I. Antony, G. Lerebours, and A. Nitenberg Angiotensin-Converting Enzyme Inhibition Restores Flow-Dependent and Cold Pressor Test–Induced Dilations in Coronary Arteries of Hypertensive Patients Circulation, December 15, 1996; 94(12): 3115 - 3122. [Abstract] [Full Text]

				E. J. Eichhorn and M. R. Bristow Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure Circulation, November 1, 1996; 94(9): 2285 - 2296. [Abstract] [Full Text]

				P. Groves, S. Kurz, H. Just, and H. Drexler Role of Endogenous Bradykinin in Human Coronary Vasomotor Control Circulation, December 15, 1995; 92(12): 3424 - 3430. [Abstract] [Full Text]